CoChat

The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

Mease, Philip J., Gottlieb, Alice B., Berman, Alberto, Drescher, Edit, Xing, Jun, Wong, Robert, Banerjee, Subhashis · 2016 · Arthritis & Rheumatology
Cited by 152

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective: To evaluate the efficacy of clazakizumab, a monoclonal antibody with high affinity and specificity for the interleukin‐6 (IL‐6) cytokine, in psoriatic arthritis (PsA). Methods: In this randomized, double‐blind, placebo‐controlled, dose‐ranging study (ClinicalTrials. gov identifier: NCT01490450), patients with active PsA and an inadequate response to nonsteroidal antiinflammatory drugs were randomized (1:1:1:1) to receive subcutaneous placebo or clazakizumab 25 mg, 100 mg, or 200 mg every 4 weeks, with or without methotrexate. The primary end point was the response rate according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 16, with secondary efficacy end points at weeks 16 and 24. Results: A total of 165 patients were randomized. At week 16, the ACR20 response rate was significantly higher with clazakizumab 100 mg versus placebo (52.4% versus 29.3%; P = 0.039). ACR20 response rates at week 16 were 46.3% with clazakizumab 25 mg (P = 0.101 versus placebo) and 39.0% with clazakizumab 200 mg (P = 0.178 versus placebo). ACR50/ACR70 response rates were numerically higher with clazakizumab versus placebo at weeks 16 and 24. Compared with placebo, clazakizumab treatment significantly improved musculoskeletal manifestations (joint signs and symptoms, enthesitis, and dactylitis), with minimal improvements in skin disease, without clear evidence of a dose response. Clazakizumab was well tolerated. Conclusion: This is the first clinical trial of an IL‐6–targeted therapy in PsA. Clazakizumab may be an effective treatment option for musculoskeletal aspects of PsA, but because of the lack of a dose response in this study, further studies are required to confirm the appropriate dose. The safety profile is consistent with the pharmacology of IL‐6 blockade and prior clinical experience with this antibody in rheumatoid arthritis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.39700

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Severe Psoriasis – Oral Therapy with a New Retinoid

    Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718 · cited 4×

    “At week 24, PASI75 response rates were 12.2% for placebo, 19.5% for clazakizumab 25 mg, 28.6% for clazakizumab 100 mg, and 12.2% for clazakizumab 200 mg. Patient-reported outcomes.”
    BackgroundInfluential

Cited by

See all 152

Metadata

Authors
Mease, P. J., Gottlieb, A. B., Berman, A., Drescher, E., Xing, J., Wong, R., & Banerjee, S.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2016-08-25
Volume
68
Issue
9
Pages
2163-2173
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2342299171
Cited by
152
References
1
FWCI
17.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.